Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation

Radiol Clin North Am. 2021 May;59(3):305-322. doi: 10.1016/j.rcl.2021.01.001. Epub 2021 Mar 24.

Abstract

Molecular features are now essential in distinguishing between glioma histologic subtypes. Currently, isocitrate dehydrogenase mutation, 1p19q codeletion, and MGMT methylation status play significant roles in optimizing medical and surgical treatment. Noninvasive pretreatment and post-treatment determination of glioma subtype is of great interest. Although imaging cannot replace the genetic panel at present, image findings have shown promising signs to identify and diagnose the types and subtypes of gliomas. This article details key imaging findings in the most common molecular glioma subtypes and highlights recent advances in imaging technologies to differentiate these lesions noninvasively.

Keywords: Codeletion; Glioma molecular status; IDH; MGMT; Radiomics.

Publication types

  • Review

MeSH terms

  • Brain / diagnostic imaging
  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / genetics*
  • DNA Modification Methylases / genetics*
  • DNA Repair Enzymes / genetics*
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Magnetic Resonance Imaging / methods*
  • Methylation
  • Mutation / genetics*
  • Tomography, X-Ray Computed / methods*
  • Tumor Suppressor Proteins / genetics*

Substances

  • Tumor Suppressor Proteins
  • Isocitrate Dehydrogenase
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes